Imunon Inc Asset Resilience Ratio
Imunon Inc asset resilience ratio. Imunon Inc (IMNN) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Imunon Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Imunon Inc (2004–2024)
Asset resilience ratio of Imunon Inc from 2004 to 2024. This chart shows how Imunon Inc's Asset Resilience Ratio has changed over time. Read IMNN total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Imunon Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Imunon Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Imunon Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Imunon Inc Industry Peers by Asset Resilience Ratio
Compare Imunon Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Imunon Inc Asset Resilience Ratio by Year (2004–2024)
Imunon Inc asset resilience ratio by year from 2004 to 2024. The table below shows the annual Asset Resilience Ratio data for Imunon Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $9.72 Million | -- |
| 2023-12-31 | 44.97% | $9.86 Million | $21.92 Million | -3.36pp |
| 2022-12-31 | 48.33% | $21.25 Million | $43.98 Million | +8.08pp |
| 2021-12-31 | 40.25% | $29.80 Million | $74.05 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $37.53 Million | -- |
| 2019-12-31 | 20.86% | $7.99 Million | $38.28 Million | -9.57pp |
| 2018-12-31 | 30.43% | $14.26 Million | $46.86 Million | +3.65pp |
| 2017-12-31 | 26.78% | $12.72 Million | $47.51 Million | +21.33pp |
| 2016-12-31 | 5.45% | $1.68 Million | $30.85 Million | -16.58pp |
| 2015-12-31 | 22.03% | $10.80 Million | $49.03 Million | -14.22pp |
| 2014-12-31 | 36.24% | $24.17 Million | $66.69 Million | -45.11pp |
| 2013-12-31 | 81.36% | $37.16 Million | $45.67 Million | +49.66pp |
| 2012-12-31 | 31.70% | $8.04 Million | $25.36 Million | +0.59pp |
| 2011-12-31 | 31.11% | $10.16 Million | $32.65 Million | +15.45pp |
| 2010-12-31 | 15.66% | $395.56K | $2.53 Million | -22.80pp |
| 2009-12-31 | 38.47% | $5.70 Million | $14.81 Million | +21.32pp |
| 2008-12-31 | 17.15% | $4.06 Million | $23.69 Million | +9.46pp |
| 2007-12-31 | 7.68% | $3.00 Million | $39.04 Million | -34.58pp |
| 2006-12-31 | 42.26% | $8.00 Million | $18.93 Million | +4.55pp |
| 2005-12-31 | 37.71% | $6.00 Million | $15.91 Million | -20.33pp |
| 2004-12-31 | 58.04% | $9.90 Million | $17.05 Million | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase fo… Read more